A phase II study of zandelisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma: ME-401-K02 study.
Munakata W, Kumode T, Goto H, Fukuhara N, Shimoyama T, Takeuchi M, Kawakita T, Kubo K, Sawa M, Uchida T, Mishima Y, Ichii M, Hanaya M, Matsumoto A, Kuriki M, Seike T, Izutsu K, Ishizawa K.
Munakata W, et al. Among authors: takeuchi m.
Br J Haematol. 2025 Jan 8. doi: 10.1111/bjh.19994. Online ahead of print.
Br J Haematol. 2025.
PMID: 39778876